June 7, 2021 10:05 AM EDTUpdated June 10, 02:50 AM
FDA+

No­vo Nordisk scores a win for semaglu­tide in obe­si­ty, po­ten­tial­ly set­ting up a next-gen bat­tle with Eli Lil­ly

Nicole DeFeudis

Editor

No­vo Nordisk pulled a high­ly an­tic­i­pat­ed win for its GLP-1 ther­a­py semaglu­tide in obe­si­ty on Fri­day, be­com­ing the first com­pa­ny to get a chron­ic weight …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

Ex­clu­sive: In­sitro makes head­way on the hard­er road, dis­cov­er­ing new ALS drug tar­get

A service from the Financial Times